Search

Displaying results 2051 - 2060 of 4590 in total
  1. Drug

    Phenoxypropazine

    go.drugbank.com/drugs/DB09251
    ApprovedWithdrawn

    It was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential.

  2. Drug

    Monobenzone

    go.drugbank.com/drugs/DB00600
    ApprovedWithdrawn

    It exerts a depigmenting effect on skin of mammals by increasing the excretion of melanin from the melanocytes. It may also cause destruction of melanocytes and permanent depigmentation.

  3. Drug

    Pivhydrazine

    go.drugbank.com/drugs/DB09252
    ApprovedWithdrawn

    In 1960, it was widely used as an antidepressant agent but it is now discontinued.

  4. Drug

    Lanreotide

    go.drugbank.com/drugs/DB06791
    ApprovedInvestigational

    Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome … Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.

  5. Drug

    Trimebutine

    go.drugbank.com/drugs/DB09089
    ApprovedInvestigational

    Trimebutine is not a FDA-approved drug, but it is available in Canada and several other international countries.

  6. Drug

    Allogeneic processed thymus tissue

    go.drugbank.com/drugs/DB16736
    Approved

    [L38929] Congenital athymia is a rare condition that leads to the absence of a thymus at birth and a high premature mortality rate, with patients typically dying by age two or three. … Allogeneic processed thymus tissue implantation works by migrating the recipient’s bone marrow-derived stem cells to the implanted cultured thymus tissue that develops immunocompetent naïve T cells.

  7. Drug

    Chlorzoxazone

    go.drugbank.com/drugs/DB00356
    Approved

    It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)

  8. Drug

    Cimlanod

    go.drugbank.com/drugs/DB14983
    Investigational

    Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers)

  9. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    [L39850] Avacopan was approved by Health Canada on April 20, 2022.[L41650] … [A240269, A240329, L38919] Avacopan was granted FDA approval on October 8, 2021, and is currently marketed under the name TAVNEOS by ChemoCentryx, Inc.

  10. Drug

    Felodipine

    go.drugbank.com/drugs/DB01023
    Approved

    It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. … By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction.